Explainer
The 503A Bulks List, Explained: How the FDA Decides Which Peptides Pharmacies Can Compound
The 503A Bulks List controls which non-approved substances compounding pharmacies can legally prepare. Here is how it works, how 503A differs from 503B, and why it decides peptide access in the US.
Quick answer
The 503A Bulks List is the FDA's roster of bulk drug substances that state-licensed compounding pharmacies may compound without an FDA-approved product. A peptide that is not FDA-approved and not on the list generally cannot be legally compounded for patients, which is why the July 2026 review of BPC-157, TB-500 and five other peptides directly determines their access.
Key takeaways
- →Compounding lets a pharmacy prepare a medication that is not commercially available as an FDA-approved product, under specific legal limits.
- →503A covers patient-specific prescriptions; 503B covers larger-batch outsourcing facilities under stricter manufacturing rules. Each has its own bulks list.
- →A non-approved substance must be on the relevant bulks list to be compounded legally, which is what the PCAC votes on.
- →For most research peptides, the 503A pathway is the only regulated route to a prescription product, so a bulks-list exclusion effectively ends legal access.
Most debates about peptide legality come down to one obscure document: the FDA's 503A Bulks List. Understanding it explains why a compound like BPC-157 can be dispensed by a licensed pharmacy in one scenario and sold only as a 'not for human use' research chemical in another. Here is the short, practical version.
What compounding actually is
Compounding is the preparation of a customized medication by a licensed pharmacy for a patient who cannot use a standard commercial product, or when no approved product exists in the needed form or strength. It is legal and long-standing, but it operates inside guardrails set by Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.
503A versus 503B
- 503A: traditional pharmacies compounding patient-specific prescriptions. They may use a bulk substance only if it is FDA-approved, appears in an applicable USP monograph, or is on the 503A Bulks List.
- 503B: registered outsourcing facilities that compound larger batches under cGMP-style manufacturing standards, using their own separate bulks list. This is the route for office-stock volumes.
Why the bulks list is the whole game for peptides
Because none of the popular research peptides is FDA-approved, their only regulated, prescription-based route runs through a bulks list. If a peptide is on the 503A list, a licensed pharmacy can compound it for a patient with a valid prescription. If it is not, that same preparation is generally not permitted, and demand tends to move to unregulated research-chemical suppliers with no clinical oversight or batch testing.
How a substance gets evaluated
Substances are nominated, then reviewed by the FDA and the Pharmacy Compounding Advisory Committee against statutory criteria: how well the substance is physically and chemically characterized, its safety and effectiveness evidence, and its historical use in compounding. The committee votes to recommend adding or not adding each one, and the FDA makes the final call. The July 2026 PCAC meeting is exactly this process, applied to seven peptides at once.
Frequently asked questions
Is compounding legal?+
Yes. Pharmacy compounding is legal under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, within defined limits on which substances may be used and how they are prepared.
Can a pharmacy compound any peptide a doctor prescribes?+
No. For a non-approved substance, the pharmacy generally needs it to be on the applicable bulks list. A prescription alone does not make an off-list bulk substance compoundable.
Is a research-chemical peptide the same as a compounded one?+
No. Research chemicals are sold outside the regulated supply chain, typically labeled 'not for human use,' with no pharmacy oversight, prescription, or guaranteed testing. A compounded prescription comes from a licensed pharmacy.
Sources
- 1.Compounding and the FDA: Questions and Answers (503A and 503B overview) · U.S. Food & Drug Administration
- 2.Bulk Drug Substances That Can Be Used in Compounding Under Section 503A · U.S. Food & Drug Administration